Breaking Finance News

Gilead Sciences, Inc. (NASDAQ:GILD) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $80.00, Gilead Sciences, Inc. (NASDAQ:GILD) traded -0.91% lower on the day. With the last stock price down -6.12% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. GILD has recorded a 50-day average of $79.46 and a two hundred day average of $85.89. Trade Volume was down over the average, with 7,037,313 shares of GILD changing hands under the typical 10,680,600

Zacks Investment Research has upgraded Gilead Sciences, Inc. (NASDAQ:GILD) to Hold in a statement released on Monday September 26, 2016.

Recent Performance Chart

Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. has PE ratio of 7.08 with a one year low of $76.67 and a one year high of $111.11 and has a market capitalization of $0.

A total of 19 brokerages have issued a ratings update on Gilead Sciences, Inc.. Seven brokerages rating the company a strong buy, nine brokerages rating the company a buy, nine brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $111.05.

General Company Details For Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.